Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00020501 · ClinicalTrials.gov registry record · Phase 3
Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver
A Phase 3 study of Colorectal Cancer and Metastatic Cancer, sponsored by National Institutes of Health Clinical Center (CC).
- Completed
- Registry status
- Phase 3
- Development phase
- 1
- Study location
NCT00020501: Completed Phase 3 study of Colorectal Cancer and Metastatic Cancer, sponsored by National Institutes of Health Clinical Center (CC).
NCT00020501 is a Phase 3 study of Colorectal Cancer and Metastatic Cancer that has completed, run by National Institutes of Health Clinical Center (CC). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00020501, a Phase 3 study of Colorectal Cancer and Metastatic Cancer, has completed, sponsored by National Institutes of Health Clinical Center (CC).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells. It is not yet known which chemotherapy regimen is most effective for colorectal cancer that has spread to the liver. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without isolated hepatic perfusion with melphalan in treating patients who have colorectal cancer that has spread to the liver.
Conditions Studied
Interventions
- DRUG fluorouracil
- DRUG leucovorin calcium
- DRUG floxuridine
- DRUG irinotecan hydrochloride
- DRUG FOLFIRI regimen
Study Locations (1)
Maryland
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support - Bethesda
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-03 |
| Est. Completion | 2005-01 |
| Phase | Phase 3 |
What the finished NCT00020501 record still lists
NCT00020501 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 2 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 5 interventions - of which fluorouracil is the first listed.
NCT00020501 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00020501 about?
NCT00020501 is a clinical study titled "Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells. It is not yet known which chemotherapy regimen is most effective for colorectal cancer tha...
What is the current status of trial NCT00020501?
This trial is currently completed. It is a Phase 3 study. The study started on 2001-03. Estimated completion is 2005-01.
What conditions does trial NCT00020501 study?
This clinical trial studies the following conditions: Colorectal Cancer, Metastatic Cancer.
What interventions are being tested in trial NCT00020501?
The interventions under investigation include: fluorouracil (DRUG), leucovorin calcium (DRUG), floxuridine (DRUG), irinotecan hydrochloride (DRUG), FOLFIRI regimen (DRUG).
Who is sponsoring clinical trial NCT00020501?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00020501 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
RECRUITING · Phase 3
-
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 3
-
The Northern-European Initiative on Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery
COMPLETED · Phase 3
-
A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
COMPLETED · Phase 3
-
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia